BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

OriCell Advances First GPC3 CAR T Therapy Into Confirmatory Phase II Trial for Advanced Liver Cancer

OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101,...

June 08, 2026 | News

Kexing Biopharm Advances GB10 Into Phase I Trial For Neovascular AMD In China

Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently d...

June 08, 2026 | News

Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...

June 08, 2026 | News

Correctseq Reports 15 Month Crisis Free Outcome in First Sickle Cell Disease Patient Treated With CS 206

CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for ...

June 04, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

June 04, 2026 | News

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

Lynk Pharmaceuticals Advances LNK01004 Into Phase II Trials For Vitiligo And Chronic Hand Eczema

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

June 02, 2026 | News

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ribo Submits Phase 2 CTA To EMA For siRNA Therapy Targeting Coronary Artery Disease

Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application...

May 29, 2026 | News

CGBIO Expands Global NOVOSIS Partnership With DePuy Synthes Into North America And Australia

DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development...

May 28, 2026 | News

Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...

May 28, 2026 | News

Pierre Fabre Laboratories Receives CHMP Positive Opinion For BRAFTOVI Combination In First Line BRAF Mutant Metastatic Colorectal Cancer

This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination w...

May 27, 2026 | News

AGC Biologics Selected By Teikoku Seiyaku Co., Ltd. To Advance Microbial Manufacturing For KTP 001 Disc Herniation Therapy

AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract d...

May 27, 2026 | News

Caliway Advances Global Phase 3 Programme For CBL 514 Following U.S. FDA IND Clearance

Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy ...

May 26, 2026 | News

Stay Connected